Triarco Receives Patentfor ALPHASTAT™

Triarco Receives Patentfor ALPHASTAT™

WAYNE, N.J.--Triarco Industries received a U.S. patent (No. 6,277,417) for its trademark ingredient ALPHASTAT™. The ingredient is a composition including astaxanthin and saw palmetto. It is designed to inhibit the activity of 5-alpha-reductase, the key enzyme attributed to benign prostatic hyperplasia (BPH).

Triarco's patent covers the method of inhibiting the activity of the enzyme in humans by administering the antioxidant composition. The patent abstract noted that the composition "is useful to prevent and treat[BPH] and prostate cancer in human males." According to Triarco (www.triarco.com), ALPHASTAT is available in oil form, suitable forsoftgels; it added that the ingredient is most stable blended into oils to protect the carotenoids against oxidation and maximize stability.